Cyclacel Pharmaceuticals Reports First Quarter 2021 Financial Results
– Announces IND Authorization by FDA for Fadraciclib, a CDK2/9 Inhibitor, in Solid Tumors – – Recent Publication Reported that Overactive…
Pharmaceuticals, Biotechnology and Life Sciences
– Announces IND Authorization by FDA for Fadraciclib, a CDK2/9 Inhibitor, in Solid Tumors – – Recent Publication Reported that Overactive…
SEATTLE, May 12, 2021 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development…
DURHAM, N.C., May 12, 2021 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the Company”), a global leader in…
BASKING RIDGE, NJ, May 11, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE…
EXTON, Pa., May 11, 2021 (GLOBE NEWSWIRE) — Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO)…
PARIS, May 11, 2021 (GLOBE NEWSWIRE) — Cellectis S.A. (NASDAQ: CLLS – Euronext Growth: ALCLS), a clinical-stage biotechnological company employing…
U.S. IXPLORE Phase II trial achieved its objective; vilobelimab was shown to be safe and well tolerated in patients with…
CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic…
Progressing ALRN-6924: on track to initiate Phase 1b randomized placebo-controlled trial in patients with p53-mutated non-small cell lung cancer in…
OTO-313 Phase 2 trial in tinnitus initiated with results expected in mid-2022OTO-413 Phase 1/2 trial expansion in hearing loss expected…